Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Using a micro-organism to make a protein or polypeptide
Reexamination Certificate
2005-12-07
2008-11-04
Kam, Chih-Min (Department: 1656)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Using a micro-organism to make a protein or polypeptide
C435S252700, C435S253600, C424S236100, C424S239100
Reexamination Certificate
active
07445914
ABSTRACT:
Media and processes for the fermentation ofClostridium botulinumand obtaining abotulinumtoxin for use in formulatingbotulinumtoxin pharmaceutical compositions. The growth media can contain significantly reduced levels of meat or dairy by-products using non-animal based products to replace the animal-derived products. Preferably, the media used are substantially free of animal derived products.
REFERENCES:
patent: 4401683 (1983-08-01), Thompson
patent: 6558926 (2003-05-01), Demain et al.
patent: 6818409 (2004-11-01), Oguma
patent: 7354470 (2005-10-01), Xiang et al.
patent: 7148041 (2006-12-01), Donovan
patent: 7160699 (2007-01-01), Wang et al.
patent: 2003/0118598 (2003-06-01), Hunt et al.
patent: 2004/0235139 (2004-11-01), Demain et al.
patent: WO 94/09115 (1993-10-01), None
patent: WO 1996/005222 (1996-02-01), None
patent: WO 98/54296 (1998-05-01), None
patent: WO 01/05997 (2000-07-01), None
patent: WO 01/05997 (2000-07-01), None
patent: WO 01-36655 (2000-10-01), None
patent: WO 01/58472 (2001-02-01), None
patent: WO 2005/035749 (2005-04-01), None
Young-Perkins et al. , J. Food Science 52, 1084-1088 (1987).
Coligan, et al.,Current protocols in protein science, Front Matter, Aug. 2003.
Lungdahl, L.G., et al., Working with anaerobic bacteria,Manual of Industrial Microbiology and Biotechnology, Chp. 8, 1986, pp. 84-96.
Mueller, J.H., et al., Variable factors influencing the product of tetanus toxin,J. Bacteriol, 1954; 67:271-7.
Ozutsumi, K., et al., Rapid, simplified method for production and purification of tetanus toxin,Applied and Environmental Microbiology, Apr. 1985, vol. 49, No. 4, pp. 939-943.
Chp. 1, pp. 1-88, Strategies of Protein Purification and Characterization,Current Protocols in Protein Science, Front Matter, (2003) John E. Coligan, et al., Ed, Chp. 21, pp. 1-282.
Chp. 21, pp. 1-282, Peptidases,Current Protocols in Protein Science, Front Matter, (2003) John E. Coligan, et al., Ed.
Naumann, M., et al., Botulinum toxin type A in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions,Euro. J. Neurology1999:6(Suppl 4):S111-S115.
Porfirio, Z., et al., Specific peptides of casein pancreatic digestion enhance the production of tetanus toxin,J. of Applied Microbiology, 1997 83:678-684.
Ragona, Rosario Marchese, et al., Management of Parotid Sialocele with botulinum toxin,The Laryngoscope, 109:Aug. 1999:pp. 1344-1346.
Siegel, L.S., Fermentaton kinetics of botulinum toxin production (types A, B and E),Biomedical aspects of botulism, New York: Academic Press 1981:pp. 121-128.
Schantz, E.J., et al., Preparation and characterization of botulinum toxin type A for human treatment, Jankovic J, ed.;Neurological Disease and Therapy. Therapy withBotulinum Toxin, 1994;25:pp. 41-49.
Schantz, E.J., et al., Properties and use of botulinum toxin and other miorobial neurotoxins in medicine,Microbiological Reviews, Mar. 1992, p. 80-99.
Schiefer-Ullrich, H., et al., Comparative studies on physiology and taxonomy of obligatory purinolytic clostridia,Arch Microbiol, 1984, 138:345-353.
Whitmer, M.E., et al., Development of improved defined media for clostridium botulinum serotypes A, B and E,Applied and Environmental Microbiology, Mar. 1988, vol. 54, No. 3, p. 753-759.
Heenan, C. N., et al., Lehensm.-Wiss. U.-Technol, 35 (2002), pp. 171-176.
Miwa, Norinaga, et al., International Journal of Food Microbiology, 49 (1999), pp. 103-106.
Mueller, J. H., et al., J. Bacteriology, Mar. 1954, 67(3), pp. 271-277.
Whitmer, M. E., et al., Applid and Environmental Microbiology, Mar. 1988, 54(3), pp. 753-759.
Oxoid—Product CM0149—product description, pp. 1-2. (2004).
Bonventre, P.F., et al., Physiology of toxin production by clostridium botulinum types A and B,College of Medicine, vol. 7, pp. 372-374, (1959).
Chen, F., et al., Biophysical characterization of the stability of the 150-kilodalton botulinum toxin, the nontoxic component and the 900-kilodalton botulinum toxin complex species,Infect Immun Jun. 1998; 66(6):2420-2425.
Holdeman, L., et al., A study of the nutritional requirements and toxin production of clostridium botulinum type F,Canadian Journal of Microbiology, vol. 11, (1965), pp. 1009-1019.
Johnson, E., et al., Clostridium botulinum and its neurotoxins: a metabolic and cellular perspective,Toxicon 39(2001) 1703-1722.
Karasawa, T., et al., A defined growth medium for clostridium difficle,Microbiology(1995), 141, 371-375.
Kohl, A., et al., Comparison of the effect of botulinum toxin A (Botox®) with the highly-purified neurotoxin (NT201) n the extensor digitorum brevis muscle test,MOV Disord, 2000;15(Suppl 3):165.
Lewis, K.H., et al., Practical media and control measures for highly toxic cultures of clostridium botulinum type A,Production of Botulinum Toxin, pp. 213-230, 1947.
Li, Y., et al., Expression and characterization of the heavy chain of tetanus toxin: reconstitution of the fully-recombinant dichain protein in active form,J Biochem(Tokyo) Jun. 1999;125(6):1200-1208.
Bedu-Addo, F., et al. “Use of Biophysical characterization in preformulation development of a heavy-chain fragment of botulinum serotype B: Evalution of suitable purification process conditions.”Pharmaceutical Research21.8 (2004): 1353-1361.
Byrne, M., et al. “Purification, potency, and efficacy of the botulinum type A binding domain from Pichia Pastoris as a recombinant vaccine candidate. ”Infection and Immunity66.10 (1998): 4817-4822.
Gessler, F., et al. “Production and purification of Clostridium botulinum type C and D neurotoxin. ”FEMS Immunology and Medical Microbiology24 (1999): 361-367.
Gimenez, J., et al., “Simplified purification method for Clostridium botulinum type E toxin. ”Applied and Environmental Microbiology53.12 (Dec. 1987): 2827-2830.
Huhtanen, C.N. “Some observations on a perigo-type inhibition of Clostridium botulinum in a simplified medium. ”Journal of Milk and Food Technology38.12 (Dec. 1975): 761-763.
Johnson, S., et al. “Scale-up of the fermentation and purification of the recombinant heavy chain fragment C of botulinum neurotoxin serotype F, expressed in Pichia Pastoris,”Protein Expression and Purification32 (2003): 1-9.
Kozaki, S., et al. “Immunological characterization of papain-induced fragments of Clostridium botulinum type A neurotoxin and interaction of the fragments with brain synaptosomes. ”Infection and Immunity57.9 (1989): 2634-2639.
Prabakaran, S., et al., “Botulinum neurotoxin types B and E: Purification, limited proteolysis by endoproteinase Glu-C and Pepsin, and comparison of their indentified cleaved sites relative to the three-dimensional structure of type A neurotoxin. ”Toxicon39 (2001): 1515-1531.
Schantz, E.J., et al., Lewis, G.E. “Use of Chrystalline type A botulinum toxin in medical research. ”Biomedical Aspects of Botulism, Academic Press, Inc., George E. Lewis, Jr., Ed., 1981: 143-150.
Siegel, L.S. “Toxin production by Clostridium botulinum type A under various fermentation conditions. ”Applied and Environmental MicrobiologyOct. 1979: 606-611.
Tse, et al.,European Journal of Ciochemistry122 (1982): 493-500.
Weatherly, G., et al., “Initial purification of recombinant botulinum neurotoxin fragments for pharmaceutical production using hydrophobic charge induction chromatography. ”Journal of Chromatography A952 (2002): 99-110.
Allergan Inc.
Donovan Stephen
Kam Chih-Min
Nassif Claude L.
Voet Martin
LandOfFree
Animal product free media and processes for obtaining a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Animal product free media and processes for obtaining a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Animal product free media and processes for obtaining a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4034451